Cost-Effectiveness Analysis of Teneligliptin V/S Glimepiride as an Add-on to Metformin in Type 2 Diabetes Mellitus

Manju C S; Greeshma Gireesh; . Hasna

doi:10.18502/jppm.v11i2.20278

Manju C S Govt Medical College, Kozhikode, affiliated to Kerala University of Health Sciences, India.
Greeshma Gireesh Govt Medical College, Kozhikode, affiliated to Kerala University of Health Sciences, India.
. Hasna Govt Medical College, Kozhikode, affiliated to Kerala University of Health Sciences, India.

DOI: https://doi.org/10.18502/jppm.v11i2.20278

Keywords: Diabetes mellitus, Cost effectiveness, Metformin hydrochloride, Glimepiride, Teneligliptin

Abstract

Background: Diabetes is a major lifestyle disorder. Proper glycemic control is needed to prevent the development of patients with Type 2 diabetes. Glimepiride is a second- generation sulphonyl urea with better safety and efficacy, and is commonly prescribed compared to other drugs of that class. teneligliptin is a relatively newer dipeptidyl peptidase inhibitor with proven clinical efficacy with metformin. A more cost-effective treatment option is important in the case of people with a poor economic background for better adherence and thereby preventing complications and economic burden.

Methods: A prospective observation study was conducted in a tertiary care hospital to assess and compare the cost-effectiveness of glimepiride 1mg and teneligliptin 20 mg when added to metformin 500 mg. a total of 112 patients were selected as per the inclusion criteria, 56 of them allocated to group A are taking glimepiride 1 mg and metformin 500 mg once daily. Group B patients are those who are on teneligliptin 20 mg and metformin 500 mg once daily. Fasting blood glucose and post-prandial blood glucose of each patient in both groups were recorded as baseline.

Results: The average cost-effectiveness ratio is calculated using the average cost of therapy for 4 months and the average reduction in effectiveness for 4 months. In this study, cost data included direct costs of purchasing the drugs. cost-effectiveness analysis revealed that glimepiride metformin combination showed better effectiveness in terms of both FBG and PPBG reduction. Teneligliptin and metformin therapy have shown satisfactory reduction in blood glucose levels, but it is much costlierCompared to teneligliptin, glimepiride is a better choice as an add-on drug in the absence of any contraindication in patients who are highly concerned about cost, to reduce economic burden, and to improve adherence, when used as an initial combination in patients with Type 2 diabetes mellitus.